BioNexus Gene Lab Corp Files 8-K

TL;DR

BioNexus Gene Lab Corp. filed an 8-K on April 18, 2024, updating corporate info and financial statements.

AI Summary

BioNexus Gene Lab Corp. filed an 8-K on April 18, 2024, to report on other events and financial statements. The filing details the company's incorporation in Wyoming and provides its business and mailing addresses in Kuala Lumpur, Malaysia. It also lists the company's IRS number and former name.

Why It Matters

This filing provides essential corporate information and updates for BioNexus Gene Lab Corp., which may be relevant for investors and stakeholders tracking the company's regulatory compliance and operational details.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.

Key Players & Entities

• BioNexus Gene Lab Corp. (company) — Registrant
• April 18, 2024 (date) — Date of earliest event reported
• Wyoming (jurisdiction) — State of incorporation
• Kuala Lumpur (location) — Business and mailing address city
• 262124961 (identifier) — IRS Employer Identification No.

FAQ

Filing Documents

• bglc_8k.htm (8-K) — 25KB
• bglc_ex991.htm (EX-99.1) — 41KB
• bglc_ex991img6.jpg (GRAPHIC) — 59KB
• 0001477932-24-002229.txt ( ) — 282KB
• bion-20240418.xsd (EX-101.SCH) — 6KB
• bion-20240418_lab.xml (EX-101.LAB) — 15KB
• bion-20240418_cal.xml (EX-101.CAL) — 1KB
• bion-20240418_pre.xml (EX-101.PRE) — 10KB
• bion-20240418_def.xml (EX-101.DEF) — 2KB
• bglc_8k_htm.xml (XML) — 4KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure On April 18, 2024, the Company issued the press release attached hereto as Exhibit 99.1. The information in this Item 7.01 of this Current Report shall not be deemed "filed" for any purpose, including for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section. The information in this Current Report on Form 8-K shall not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act regardless of any general incorporation language in such filing. The filing of this report and the furnishing of this information pursuant to Item 7.01 do not mean that such information is material or that disclosure of such information is required.

01. Other Events

Item 8.01. Other Events. As stated in the attached Press Release, the Company made a strategic investment through its wholly owned subsidiary, MRNA Scientific Sdn Bhd, in Ascension Innovation Sdn Bhd, a Malaysian company.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits . 99.1 Press Release of the Company dated April 18, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioNexus Gene Lab Corp. Date: April 18, 2024 By: /s/ Su-Leng Tan Lee Name: Su-Leng Tan Lee Title: Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR